|Description||LY2874455 exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.|
|Synonyms||LY2874455; LY 2874455; LY-2874455.|
|Current Developer||Eli Lilly.|
LY2874455 exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activit...
SSR128129E free acid
SSR128129E free acid is a multi-FGFR blocker with allosteric properties. It inhibits FGFR signaling by binding to the extracellular FGFR domain without affectin...
E 3810 dihydrochloride is a dual VEGFR/FGFR tyrosine kinase inhibitor. It suppresses the tumor angiogenesis and tumor cell proliferation via inhibiting VEGFR1, ...
BLU-554 is a potent and selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) (IC50 = 5 nM), which is promisingly to be used for the treatment of h...
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59...
FIIN-2 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. FIIN-2 is the first inhibitor that can potently inhibit the prolife...
This active molecular is a Axl receptor tyrosine kinase inhibitor, Proto oncogene protein c met inhibitor, Type-1, Type-2 and Type-3 fibroblast growth factor re...
PD173074 is a small-molecule FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines. PD173074 suppressed cell prol...